mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
== Neutrophil antigens == There are five (HNA 1–5) sets of neutrophil antigens recognized. The three HNA-1 antigens (a-c) are located on the low affinity Fc-γ receptor IIIb (FCGR3B :CD16b) The single known HNA-2a antigen is located on CD177. The HNA-3 antigen system has two antigens (3a and 3b) which are located on the seventh exon of the CLT2 gene (SLC44A2). The HNA-4 and HNA-5 antigen systems each have two known antigens (a and b) and are located in the β2 integrin. HNA-4 is located on the αM chain (CD11b) and HNA-5 is located on the αL integrin unit (CD11a).
===== Epidermis ===== The entire surface of the plant consists of a single layer of cells called epidermis or surface tissue. The entire surface of the plant has this outer layer of the epidermis. Hence, it is also called surface tissue. Most of the epidermal cells are relatively flat. The outer and lateral walls of the cell are often thicker than the inner walls. The cells form a continuous sheet without intercellular spaces. It protects all parts of the plant. The outer epidermis is coated with a waxy thick layer called Cutin, which prevents loss of water. The epidermis also consists of stomata (singular:stoma), which helps in transpiration.
Brenda Cecilia Agüero (born 2 June 1995) is an Argentine serial killer and former neonatal nurse convicted of the murder of five babies under her care. Between March and June 2022, Agüero deliberately injected healthy babies with overdoses of potassium or insulin (or both), killing five and causing decompensations in eight others. Agüero was charged with five counts of "aggravated murder for applying the insidious method of potassium incompatible with life". Agüero was later charged with eight other counts of attempted murder. The trial against Agüero and 10 provincial officials began on 6 January 2025. On 18 June 2025, Agüero was found guilty of all charges and sentenced to life in prison.
== See also == Breast hypertrophy – Rare human disease Male bra – Pieces of clothing that fit tightly around the skinPages displaying short descriptions of redirect targets Male lactation – Production of milk in male mammals Mammoplasia – Normal or spontaneous enlargement of breasts
Sources: en.wikipedia.org
A YouGov poll for The Times puts Reform UK ahead of the Conservatives for the first time, with Reform on 19% and the Conservatives on 18%; the poll prompts Reform leader Nigel Farage to say his party is "now the opposition to Labour". ITV holds a debate featuring senior figures from the UK's seven main political parties and moderated by Julie Etchingham. 14 June – Data published by the Electoral Commission indicates that Labour raised £351,990 more in donations than the Conservatives during the first week of the general election campaign. BBC Wales sees a series of text messages from the mobile phone of Welsh Conservative Senedd member Laura Anne Jones in which she appears to ask an employee to maximise her expenses claims. Jones is subsequently asked to step back from Wales's Shadow Cabinet as a result of the revelation. A coalition of commercial media and content businesses write to Labour to urge them not to introduce advertising on the BBC, fearing it could have a negative impact on consumers, licence fee payers and creative industries. The Independent Parliamentary Standards Authority clears Douglas Ross of misusing his travel expenses following an investigation. Labour's Rosie Duffield, who is campaigning to be re-elected as MP for Canterbury, says she has withdrawn from hustings events because she does not feel safe; Duffield has previously faced death threats for her stance on sex and gender.
The first atomic bomb test, codenamed "Trinity "and detonated on July 16, 1945, near Alamogordo, New Mexico, used plutonium as its fissile material. The implosion design of "Gadget", as the Trinity device was codenamed, used conventional explosive lenses to compress a sphere of plutonium into a supercritical mass, which was simultaneously showered with neutrons from "Urchin", an initiator made of polonium and beryllium (neutron source: (α, n) reaction). Together, these ensured a runaway chain reaction and explosion. The weapon weighed over 4 tonnes, though it had just 6 kg of plutonium. About 20% of the plutonium in the Trinity weapon, fissioned; releasing an energy equivalent to about 20,000 tons of TNT. An identical design was used in "Fat Man", dropped on Nagasaki, Japan, on August 9, 1945, killing 35,000–40,000 people and destroying 68%–80% of war production at Nagasaki. Only after the announcement of the first atomic bombs was the existence and name of plutonium made known to the public by the Manhattan Project's Smyth Report.
Behavior (American English) or behaviour (British English) is the range of actions of organisms, individuals, systems or artificial entities in some environment. These systems can include other systems or organisms as well as the inanimate physical environment. It is the computed response of the system or organism to various stimuli or inputs, whether internal or external, conscious or subconscious, overt or covert, and voluntary or involuntary. While some behavior is produced in response to an organism's environment (extrinsic motivation), behavior can also be the product of intrinsic motivation, also referred to as "agency" or "free will". Taking a behavior informatics perspective, a behavior consists of actor, operation, interactions, and their properties. This can be represented as a behavior vector.
Sources: en.wikipedia.org
The three substrates of this enzyme are (S)-cheilanthifoline, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and oxygen. Its products are (S)-stylopine, oxidised NADP+, and water. This enzyme belongs to the family of oxidoreductases, specifically those acting on paired donors, with O2 as oxidant and incorporation or reduction of oxygen. The oxygen incorporated need not be derived from O2 with NADH or NADPH as one donor, and the other dehydrogenated. The systematic name of this enzyme class is (S)-cheilanthifoline,NADPH:oxygen oxidoreductase (methylenedioxy-bridge-forming). This enzyme is also called (S)-cheilanthifoline oxidase (methylenedioxy-bridge-forming). This enzyme participates in alkaloid biosynthesis.
Actinium-225 decays exclusively by alpha emission. It is part of the neptunium series, for it arises as a decay product of neptunium-237 and its daughters such as uranium-233 and thorium-229. It is the last nuclide in the chain with a half-life over a day until the penultimate product, bismuth-209 (half-life 2.01×1019 years). The final decay product of 225Ac is stable 205Tl. As a member of the neptunium series, it does not occur in nature except as a product of trace quantities of 237Np and its daughters formed by neutron capture reactions on primordial 232Th and (n,2n) reactions on 238U. It is much rarer than 227Ac and 228Ac, which respectively occur in the decay chains of uranium-235 and thorium-232. Its abundance was estimated as less than 1.1×10−19 relative to 232Th and around 9.9×10−16 relative to 230Th in secular equilibrium.
Small integral membrane protein 20 (SMIM20) is a protein that in humans is encoded by the SMIM20 gene. SMIM20 acts as a prohormone to the peptide hormone phoenixin (PNX) which was discovered for the first time in 2013 in rodent sensory ganglia. Two alternate cleavage sites within SMIM20 results in two different phoenixin products, Phoenixin-14 (PNX-14) and Phoenixin-20 (PNX-20). In the study of the evolution of nervous systems, SMIM20 together with NUCB2 have been found to have deep homology across all lineages that preceded creatures with central nervous systems, bilaterians, cnidarians, ctenophores, and sponges as well as in choanoflagellates.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.